natgillin/translations-raw huggingface dataset:
A method is provided for coding at least one image split up into partitions, a current partition to be coded containing data, at least one data item of which is allotted a sign. 
Postupak kodiranja barem jedne slike podijeljene u particije, jedne trenutne particije (Bi) za kodiranje koja sadrži podatke pri čemu je barem jednom podatku dodijeljen predznak, a podaci su koeficijenti direktne transformacije, te je postupak kodiranja naznačen time da se za trenutnu particiju provode slijedeći koraci:
The method of any of claims 1 to 5, wherein the mixture in step f) comprises edible oil at a concentration of 5 to 30 (w/w) %, preferably 5 to 25 (w/w) %, more preferably 5 to 20 (w/w) %. 
Postupak iz bilo kojeg patentnog zahtjeva 1 do 5, naznačen time, da smjesa u fazi d) sadrži jestivo ulje koncentracije 4 do 17 (w/w) %, poželjno je 8 do 17 (w/w) %, poželjnije je 9 do 17 (w/w) %.
is lower alkyl, wherein lower alkyl means an alkyl group having from 1 to 7 carbon atoms; 
i u kojoj R' je niži alkil, pri čemu niži alkil znači alkilna skupina s 1 do 7 atoma ugljika;
The CHO cell of claim 6, wherein at least one copy of the genomic sequence of the FAM60A gene, or at least 50% of coding sequence of said FAM60A gene, is deleted. 
Stanica CHO u skladu s patentnim zahtjevom 5, naznačena time što je deletirana najmanje jedna kopija genomskog slijeda gena FAM60A, ili je deletirano najmanje 50% kodirajućeg slijeda navedenog gena FAM60A.
the WPP includes a process in which probability information for entropy decoding a first largest coding unit of a thread is determined by using probability information for entropy decoding a second largest coding unit of an upper thread, wherein a predicted QP of a quantization group, which is in the current thread, and is not the current quantization group, is generated using a quantization parameter of a neighboring coding unit of the quantization group in the current thread, wherein each of the current thread and the next thread is among the plurality of threads included in the slice, 
WPP sadrži proces u kojem se informacija o vjerojatnosti za entropijsko dekodiranje prve najveće jedinice kodiranja za nit određuje korištenjem informacija o vjerojatnosti za entropijsko dekodiranje druge najveće jedinice kodiranja gornje niti, pri čemu se predviđeni QP kvantizacijske skupine, koja je u trenutnoj niti, i nije trenutna kvantizacijska skupina, generira pomoću kvantizacijskog parametra susjedne jedinice kodiranja kvantizacijske skupine u trenutnoj niti, pri čemu je svaka od trenutnih niti i sljedećih niti između mnoštva niti sadržana u odsječku, pri čemu je predviđeni QP prve kvantizacijske skupine u svakom od mnoštva niti početni QP na razini odsječka.
and R5 for each occurrence is, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; 
Ru i Rs za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran
More specifically, the sectional door comprises a plurality of panels having a shape such that they can be stacked on top of each other in a stacked state of the sectional door, and next to each other in a stored state of the sectional door. 
Sekcijska vrata (1) koja sadrže: - mnoštvo ploča (2) koje imaju oblik tako da se mogu postavljati jedna na drugu u složenom stanju sekcijskih vrata, i jedna pored druge u pohranjenom stanju sekcijskih vrata;
Vacuum distillation apparatus for separating gold-silver alloys according to claim 1, characterised in that the graphite crucible is formed with a spherical bottom. 
Aparat za vakuum destilaciju za razdvajanje zlato-srebro legura u skladu sa patentnim zahtjevom 2, naznačen time što grafitni lonac (1) je formiran sa sferičnim dnom.
The composition according to claim 8, wherein the nucleic acid is bound to the outer membrane surface of the liposome. 
Pripravak za uporabu prema zahtjevu 7, naznačen time, da je nukleinska kiselina spojena s vanjskom površinom membrane liposoma.
A pharmaceutical composition for use in the treatment or prevention of bleeding or the promotion of hemostasis in an individual, wherein the composition comprises a pharmaceutically acceptable excipient and a modified serpin as defined in any one of claims 1 to 12, a nucleic acid encoding a modified serpin as defined any one of claims 1 to 12, a vector comprising a nucleic acid encoding a modified serpin as defined any one of claims 1 to 12, or a recombinant cell comprising a vector which expresses a modified serpin as defined in any one of claims 1 to 12. 
aminokiselinsku sekvencu ostataka 25-418 od SEQ ID NO: 12 s mutacijom od E do S na ostatku 25 i s mutacijom od C do S na ostatku 256. Nukleinska kiselina, naznačena time, da ona kodira modificirani serpin prema bilo kojem od zahtjeva 1 do 13, dok je vektor, naznačen time, da obuhvaća nukleinsku kiselinu koja kodira modificirani serpin prema bilo kojem od zahtjeva 1 do 13, ili je rekombinantna stanica, naznačena time, da ona obuhvaća vektor koji izražava modificirani serpin prema bilo kojem od zahtjeva 1 do 13.
or any pharmaceutically acceptable salt, tautomer, stereoisomer, solvate, hydrate, or prodrug thereof. 
(I) Å 2O m Ho", ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
The method according to claim 2, wherein the CB1 cannabinoid receptor agonist is selected from the group consisting of HU-210 and arachidonyl-2'-chloroethylamide (ACEA). 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što se agonist kanabinoidnog receptora CB, bira iz skupine koju čine HU-210 i arahidonil-2'-kloretilamid (ACEA).
The sartan for use according to any one of claims 1 to 7, characterized in that the pharmaceutical composition is to be administered to a cat in a therapeutically effective amount once per day. 
Sartan za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se farmaceutski sastav primjenjuje na mački u terapeutski djelotvornoj količini jednom na dan.
using at least a part of the low pressure steam obtained directly from stage 1 as heat transporting fluid supplied to the reboiler of column C9, and at least a part of the medium pressure steam obtained from stage 2, after compression, as heat transporting fluid supplied to the reboilers of columns C7, C8, C10 and C11 of the complex, said columns forming a second set of columns E 2 distinct from E 1 . 
- 4) korištenje barem jednog dijela niskotlačne pare LP koja izlazi iz koraka 1 kao fluida za prijenos topline koji se dovodi u uređaj za ponovno vrenje iz kolone C9 i barem jednog dijela pare srednjeg tlaka MP koja izlazi iz koraka 2 nakon ponovne kompresije kao fluida za prijenos topline koji se dovodi u uređaje za ponovno vrenje u kolonama C7, C8, C10 i CII, sklop kolona C7, C8, C9, C101 C1I tvori sklop E2 koji je odvojen od E1.
The method of clause 50, wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Uporaba prema patentnom zahtjevu 11, naznačena time što su kognitivni poremećaji i bolesti izabrani iz grupe koju čine Alzheimer-ova bolest, oblici gubitka pamćenja i gubitak pamćenja uzrokovan starošću.
A method of treatment of inflammatory diseases, disorders and conditions characterized by or associated by excessive unregulated production of cytokines or inflammatory mediators which comprises administering to a subject a therapeutically effective amount of a compound according to claim 1 or 2 or 20. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
The plant of one of the preceding claims, comprising at least a rechargeable battery (13) of electric energy which is constantly supplied by the source of electric power (2) and which in turn supplies a plurality of low-power electric users (14), wherein the first level of importance is attributed to the rechargeable battery (13). 
Postrojenje prema jednom od prethodnih patentnih zahtjeva, koje sadrži barem punjivu bateriju (13) električne energije koja je konstantno opskrbljivana pomoću izvora električne struje (2) te koja pak opskrbljuje više niskostrujnih električnih potrošača (14), pri čemu je prva razina važnosti dodijeljena punjivoj bateriji (13).
the injection sites on the body are located at least about 1 cm, at least about 2.5 cm, at least about 5 cm, at least about 10 cm, at least about 12. 5 cm, at least about 15 cm, at least about 17.5 cm or at least about 20 cm apart from each other. 
Pripravak prema zahtjevima 6 ili 7, naznačen time da su mjesta za inokulaciju ili injekciju na tijelu smještena na udaljenosti najmanje 5 cm jedno od drugoga.
A peptide according to any one of claims 1 to 4, a nucleic acid or expression vector according to Claim 5, a host cell according to claim 6, a CTL according to claim 8, or an antibody according to claim 9 for use as a medicament in the treatment of cancer. The use according to claim 12, wherein the medicament is a vaccine. The use according to claim 12 or 13, wherein said cancer is gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 12 za upotrebu u liječenju karcinoma, kao što su gastrični, gastrointestinalni, kolorektalni karcinomi te karcinomi gušterače, pluća ili bubrega. Peptid, nukleinska kiselina ili ekspresijski vektor, stanica, aktivirani citotoksični T-limfocit za upotrebu u skladu s patentnim zahtjevom 13, pri čemu se navedeni peptidi koriste kao cjepivo.
The radio communication terminal apparatus according to claim 1, wherein, the receiver, in operation, receives higher layer control information indicating whether or not to control the transmission power value of the SRS using the second accumulation value. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 1, naznačen time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon primanja kontrolne informacije višeg sloja.
The use of a combination of the invention as defined herein for the manufacture of a medicament for the prophylaxis or treatment of any of the disease states or conditions described herein. 
Primjena soli prema jednom od zahtjeva 1 do 3 za proizvodnju lijeka za liječenje bolesti, stanja ili poremećaja pobliže opisanim u zahtjevu 10.
Method for manufacturing a laminar construction panel comprising a first metal plate (1), a second metal plate (2), and an acoustic insulation layer (3) interposed there between, characterised in that the first metal plate and the second metal plate are connected to each other by means of a number of locally welded joints, that are distributed over the laminar construction panel, and which extend through the area of the acoustic isolation layer. 
PATENTNI ZAHTJEVI Postupak proizvodnje laminarnog građevnog panela koji se sastoji od prve metalne ploče (1), druge metalne ploče (2) 1 sloja zvučne izolacije (3) smještenog između njih, naznačen time što se prvu metalnu ploču i drugu metalnu ploču spoji jednu s drugom uz pomoć više lokalno zavarenih spojeva, raspodijeljenih po laminarnom građevnom panelu, koji se pružaju kroz površinu sloja zvučne izolacije.
The isolated antibody of claim 1 selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody. 
Antitijelo iz bilo kojeg od patentnih zahtjeva 1-4 odabrano iz grupe koja se sastoji od IgG1, IgG2, poželjno IgG2a i IgG2b, IgG3, IgG4, IgM, IgA 1, IgA2, sekrecijskog IgA, IgD, i IgE antitijela.
A pharmaceutical composition comprising, together with a pharmaceutically acceptable carrier or diluent, the compound according to Claim 1, or a pharmaceutically acceptable salt or ester thereof; and an anticancer agent selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinatedcomplex compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, biological response modifiers, and other anticancer agents, wherein the definition of each anticancer agent is the same as defined in Claim 24, or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak koji sadrži, zajedno s farmaceutski prikladnim nosačem ili punilom, spoj prema bilo kojem od zahtjeva 1 do 15, ili njegovu farmaceutski prikladnu sol ili ester; i citostatik odabran iz grupe koju čine alkilirajući citostatici, antimetaboliti citostatici, citostatici antibiotici, biljni citostatici, platinom-koordinirani kompleksni spojevi citostatici, citostatici derivati kamptotecina, citostatici inhibitori tirozin kinaze, monoklonska protutijela, modulatori biološkog odgovora, i drugi citostatici, gdje je definicija svake vrste citostatika kako je dano u zahtjevu 20, ili njihovu farmaceutski prikladnu sol ili ester.
The embodiment of Figure 5 is similar to that of Figure 4. 
Realizacija sa sl. 5 je slična onoj sa sl. 4.
This mixture was evacuated and vented to H2 (repeated three times) and left on Parr shaker for 20 h under H2 (40 psi) atmosphere. 
Ova smjesa je ispražnjena i ventilirana prema H> (što je ponovljeno tri puta) i ostavljena na Parr mućkalici 20 sati pod atmosferom H, (40 psi).
G is a carboxypyridine derivative bound via an amide bond to G2, wherein G is covalently bound to L via its tertiary nitrogen and wherein G2 is an amino acid selected from the group consisting of standard amino acids, non-standard amino acids and synthetic amino acids. 
[image] pri tome je q = 1-6, [image] i G je derivat karboksipiridina koji je vezan preko amidne veze za G2, pri tome je G kovalentno vezan za L preko njegovog tercijarnog dušika i pri čemu je G2 aminokiselina odabrana iz skupine koja se sastoji od standardne aminokiseline, nestandardne aminokiseline i sintetske aminokiseline.
The ultrasound is typically applied by means of a scaler. 
Ultrazvuk se tipično primjenjuje pomoću sonde.
BACKGROUND OF THE INVENTION As is known, blenders are used for making home-made ice-cream, and normally comprise a cylindrical, horizontal-axis bowl into which the ingredients for producing a given quantity of ice-cream are poured; a cooling unit for cooling and maintaining the bowl and contents at a temperature ranging between −10° C. and −35° C.; and a rotary mixing member mounted for rotation inside the bowl to blend the ingredients at the various ice-cream-making stages. 
Kako je poznato, miješalice se koriste za kućnu izradu sladoleda i normalno se sastoje od cilindrične zdjele s horizontalnom osi, u koju se nalijevaju sastojci za proizvodnju sladoleda zadane količine; od rashladne jedinice za hlađenje i održavanje zdjele i njenog sadržaja na temperaturi u opsegu od -10"C i -35%C; te od rotacionog članka za miješanje montiranog da rotira unutar zdjele i zamiješa sastojke u različitim fazama pravljenja sladoleda.
The imaging material supply cartridge (24) of claim 12, wherein the imaging material comprises ink. 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 12, naznačen time što materijal za pisanje sadrži tintu.
The composition of claim 1, wherein the GPR119 agonist is a selective GPR119 agonist. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPRI 19 agonist je selektivni GPRI119 agonist.
providing at least one de novo papilla, 
(a) osiguravanja barem jedne de novo papile,
9 shows the discharge device 1 in the intermediate position after twisting the actuation member 17 into the discharge state. 
Slika 9 prikazuje napravu za pražnjenje 1 u međupoložaju nakon zakretanja elementa za pokretanje 17 u stanje pražnjenja.
comprising separating a racemic compound of the formula (XIII) into its enantiomers, where the compound of the formula (XIII) 
Postupak za pripravu spoja s formulom (I) uporabom spoja s formulom (XVIII)
The powder according to claim 9, wherein said process further comprises: 
Prašak prema patentnom zahtjevu 8, naznačeno time da postupak dalje obuhvaća:
Ar is phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal, LA or O(LA), 
Ar je fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal, LA ili O(LA),
A process for the preparation of compound of formula (I) as claimed in claim 1, which comprises reacting a compound of formula (II), with piperidine-4-one derivatives, using a suitable reducing agent and base in presence of suitable solvent at ambient temperature to obtain a compound of formula (I), wherein all substitutions are as defined in claim 1. 
I F2 NZ R2 H (ID sa derivatima piperidin-4-ona, uz korištenje pogodnog sredstva za redukciju i baze u prisutnosti pogodnog otapala kod temperature okoline da se dobije spoj sa formulom (I), pri čemu su sve supstitucije kako je definirano u zahtjevu 1.
Increase of the proportion of osmotically active substance. 
Broj objave europskog patenta:
A compound of formula: A pharmaceutical composition comprising the compound as described in claim 1 and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se + iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
Aspect 8. The system of aspect 1 wherein the elongate wick is slidably engages the at least one inner surface of the electric heater. 
Sustav (10) prema zahtjevu 1, pri čemu izduženi fitilj (30) klizno zahvaća najmanje jednu unutrašnju površinu električnog grijača.
A method for the preparation of a compound of general formula (IX): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, said method comprising reacting (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (I) by a method according to claim 2, or according to any one of claims 3 to 12, when dependent on claim 2. 
O NH (IX) gdje je R, vodik, alkil, halogenalkil, aralkil, cikloalkil, cikloalkilaril, aril ili piridil; izraz alkil znači linearni ili razgranati ugljikovodični lanac koji sadrži 1 - 18 atoma ugljika; izraz halogen znači fluor, klor, brom ili jod; izraz cikloalkil znači alicikličku zasićenu skupinu sa 3 do 6 atoma ugljika; te izraz aril znači nesupstituiranu fenil skupinu ili fenil supstituiran alkoksi, halogen ili nitro grupom, pri čemu spomenuti postupak sadrži reagiranje (S)-(+)-10,11- dihidro-10-hidroksi-5H-dibenz/b,Fazepin-5-karboksamida (I) postupkom prema patentnom zahtjevu 2, ili prema bilo kojem od zahtjeva 3 do 12, kad se oni pozivaju na patentni zahtjev 2.
In one embodiment, the artificial T cell receptor of the teaching comprises the amino acid sequence according to SEQ ID NO: 46 or a fragment thereof, or a variant of said amino acid sequence or fragment. 
Umjetni T stanični receptor sukladno bilo kojem od patentnih zahtjeva 6 do 10, koji sadrži aminokiselinsku sekvencu sukladno SEK ID BR: 46.
The compounds are A2A-receptor ligands, such as antagonists, agonists, reverse agonists or partial agonists, and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated. 
Spojevi su ligandi A2,-receptora, poput antagonista, agonista, reverznih agonista ili djelomičnih agonista, i korisni su u tretiranju neuroloških i psihijatriskih poremećaja gdje su implicirani A2,-receptori.
The process of claim 18, wherein the preparation of the compound of Formula L comprises the addition of an excess of LiCl in the suitable solvent in step 1) to form predominantly the L-epimer of the compound of Formula L, or the preparation of the compound of Formula L is carried out in the absence of LiCl in the suitable solvent in step 1) to form predominantly the D-epimer of the compound of Formula L, wherein the chiral center of the L-epimer or the D-epimer of the compound of Formula L is the carbon atom to which R23 is attached. 
12. Postupak sukladno patentnom zahtjevu 11, naznačeno time, da navedeno dobivanje spoja od Formule IL obuhvaća 5 dodavanje viška LiCI u navedenom odgovarajućem otapalu u koraku 1) da bi se oblikovao pretežno L epimer spoja od Formule L, ili navedeno dobivanje spoja od Formule L je izvedeno u odsutnosti LiCI da bi se oblikovao pretežito D epimer spoja od Formule I.
▪ at least one and at most two Y1, Y2, Y3, and Y4 groups represent a nitrogen atom, and 
: najmanje jedan a najviše dvije od skupina Yi, Y2, Y3i Y4 predstavljaju dušikov atom, te
The distal end of each screw 2 has external threads 21 in order to allow the screws 2 to be fixated in the spongy bone of the talus. 
- < kalkaneus-talus vijci (2) su kanulirani (22) kako bi bili navođeni pomoću cijevi vodilica te na distalnom kraju imaju narezan navoj (21) radi fiksiranja u spužvastu kost talusa;
The common plastic CD- and DVD-packaging can be bent in that angle which is needed in the process of inserting a printed paper cover between the actual packaging and the transparent foil wrapped around it. 
Uobičajeno plastično pakiranje CD-a i DVD-a može se saviti za kut koji je potreban u postupku umetanja omota od štampanog papira između ovog pakiranja i prozirne folije koja je omotana oko njega.
A door lock according to claim 7, wherein the second projection cooperates with the inner surface of the front plate that is on the side edge of the bolt opening. 
Brava prema zahtjevu 7 naznačena time da se drugo izbočenje (38) koje treba djelovati sa unutrašnjom površinom (30) nalazi na postraničnom bridu otvora spone (16).
is a substituent selected from the group consisting of i) hydrogen, ii) methyl, iii) ethyl, iv) hydroxymethyl, v) hydroxyethyl, vi) phenyl optionally substituted with 1 to 3 fluoro groups, vii) benzyl optionally substituted with 1 to 3 fluoro groups, and viii) pyridyl; 
R! je supstituent kojeg se bira iz skupine koju čine i) vodik, ii) metil, iii) etil, iv) hidroksimetil, v) hidroksietil, vi) fenil, izborno supstituiran s 1 do 3 fluome skupine, vii) benzil, izborno supstituiran s 1 do 3 fluorne skupine, te viii) piridil;
Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which 
Harl je izborno supstituiran s R6111 i/ili R6112 i monociklički je ili kondenzirani biciklički 5- do 10-eročlani nezasićeni heteroaromatski prsten, koji sadrži jedan do tri heteroatoma, od kojih se svakog bira iz skupine koju čine dušik, kisik 1 sumpor, gdje
The method as claimed in claim 2, wherein the paper is a thin raw paper with a weight of about 40-60 g/m2. 
Metoda u skladu sa patentnim zahtjevima 2 ili 3, gdje je papir (2) tanak sirov papir sa težinom od oko 40 - 60 g/m2.
The KLB agonist for use according to claim 1 in a method of treating diabetes mellitus. 
KL.f-agonist za uporabu prema zahtjevu 1, naznačen time, da služi u postupku liječenja dijabetesa mellitus.